Guggenheim lowered the firm’s price target on Structure Therapeutics (GPCR) to $90 from $92 and keeps a Buy rating on the shares after the company reiterated that top-line data from the Phase 2b ACCESS and ACCESS II studies for oral small molecule GLP1RA aleniglipron are on track for concurrent year-end 2025 readouts. The firm continues to recommend that investors build a position in advance of the ACCESS/ACCESS II readouts given what it sees as “a mismatched valuation.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Structure Therapeutics price target raised to $75 from $60 at H.C. Wainwright
- Structure Therapeutics price target lowered to $44 from $60 at Leerink
- Structure Therapeutics price target lowered to $87 from $89 at Citizens JMP
- Structure Therapeutics Reports Q2 2025 Financial Results
- Promising Developments in Structure Therapeutics’ Clinical Trials Drive Buy Rating